2024
Long-term follow-up of persons diagnosed with multidrug-resistant TB in Chennai, India, 2013–2020
Surie D, Sathyanarayanan M, Lavanya J, Smith J, Shanmugam S, Tamilzhalagan S, Selvaraj A, Ramesh G, Tripathy S, Khaparde S, Ho C, Hall-Eidson P, Ranganathan U, Selvaraju S, Moonan P. Long-term follow-up of persons diagnosed with multidrug-resistant TB in Chennai, India, 2013–2020. The International Journal Of Tuberculosis And Lung Disease 2024, 28: 54-56. PMID: 38178300, PMCID: PMC10859871, DOI: 10.5588/ijtld.23.0272.Peer-Reviewed Original ResearchAntitubercular AgentsDelivery of Health CareFollow-Up StudiesHumansIndiaTuberculosisTuberculosis, Multidrug-Resistant
2023
Retaining Patients with Drug-Resistant Tuberculosis on Treatment During the COVID-19 Pandemic — Dharavi, Mumbai, India, 2020–2022
Gomare M, Bhide S, Deshmukh R, Kaipilyawar S, Puri V, Moonan P, Khetade D, Nyendak M, Yeldandi V, Smith J, Tobias J, Date A, Joshi R, Kumar R, Ho C. Retaining Patients with Drug-Resistant Tuberculosis on Treatment During the COVID-19 Pandemic — Dharavi, Mumbai, India, 2020–2022. MMWR Morbidity And Mortality Weekly Report 2023, 72: 304-308. PMID: 36952291, PMCID: PMC10042620, DOI: 10.15585/mmwr.mm7212a2.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsCOVID-19HumansIndiaPandemicsTuberculosisTuberculosis, Multidrug-Resistant
2022
Quantifying Mycobacterium tuberculosis Transmission Dynamics Across Global Settings: A Systematic Analysis
Smith J, Cohen T, Dowdy D, Shrestha S, Gandhi NR, Hill AN. Quantifying Mycobacterium tuberculosis Transmission Dynamics Across Global Settings: A Systematic Analysis. American Journal Of Epidemiology 2022, 192: 133-145. PMID: 36227246, PMCID: PMC10144641, DOI: 10.1093/aje/kwac181.Peer-Reviewed Original ResearchMeSH KeywordsHumansMycobacterium tuberculosisTuberculosisTuberculosis, Multidrug-ResistantWhole Genome SequencingConceptsTB transmissionOngoing TB transmissionMinority of casesTuberculosis transmission dynamicsTB controlTuberculosis transmissionSecondary casesSources of heterogeneityInclusion criteriaSurveillance studyTransmission clustersInitial searchTransmission dynamicsWhole-genome sequencingPopulation levelSetting
2020
The Impact of Concurrent Antiretroviral Therapy and MDR-TB Treatment on Adverse Events.
Smith JP, Gandhi NR, Shah NS, Mlisana K, Moodley P, Johnson BA, Allana S, Campbell A, Nelson KN, Master I, Brust JCM. The Impact of Concurrent Antiretroviral Therapy and MDR-TB Treatment on Adverse Events. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2020, 83: 47-55. PMID: 31809360, PMCID: PMC6903405, DOI: 10.1097/qai.0000000000002190.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsAntitubercular AgentsCase-Control StudiesFemaleHIV InfectionsHumansMaleProspective StudiesTuberculosis, Multidrug-ResistantConceptsMultidrug-resistant tuberculosisConcurrent antiretroviral therapyMDR-TB patientsMDR-TB treatmentLaboratory adverse eventsAdverse eventsHIV coinfectionAntiretroviral therapyHIV statusConcurrent treatmentCommon clinical adverse eventsCommon laboratory adverse eventsCo-infected participantsColor discrimination testingMDR-TB therapyAntiretroviral therapy initiationFrequent adverse eventsClinical adverse eventsProspective observational studyFavorable treatment outcomesColor discrimination lossesTherapy initiationConcurrent therapyCreatinine clearanceVision loss
2017
Improved Survival and Cure Rates With Concurrent Treatment for Multidrug-Resistant Tuberculosis–Human Immunodeficiency Virus Coinfection in South Africa
Brust JCM, Shah NS, Mlisana K, Moodley P, Allana S, Campbell A, Johnson BA, Master I, Mthiyane T, Lachman S, Larkan LM, Ning Y, Malik A, Smith JP, Gandhi NR. Improved Survival and Cure Rates With Concurrent Treatment for Multidrug-Resistant Tuberculosis–Human Immunodeficiency Virus Coinfection in South Africa. Clinical Infectious Diseases 2017, 66: 1246-1253. PMID: 29293906, PMCID: PMC5888963, DOI: 10.1093/cid/cix1125.Peer-Reviewed Original ResearchConceptsCells/mm3Immunodeficiency virus coinfectionAntiretroviral therapyMDR tuberculosisCD4 countVirus coinfectionConcurrent treatmentTreatment outcomesHuman immunodeficiency virus (HIV) coinfectionUndetectable HIV viral loadConcurrent antiretroviral therapyMDR tuberculosis patientsHIV viral loadMultidrug-resistant tuberculosisStrong risk factorTuberculosis-HIVTuberculosis outcomesAdverse eventsTuberculosis patientsImproved survivalMedian agePrimary outcomeHIV statusViral loadCure rate
2015
Why healthcare workers are sick of TB
von Delft A, Dramowski A, Khosa C, Kotze K, Lederer P, Mosidi T, Peters JA, Smith J, van der Westhuizen HM, von Delft D, Willems B, Bates M, Craig G, Maeurer M, Marais BJ, Mwaba P, Nunes EA, Nyirenda T, Oliver M, Zumla A. Why healthcare workers are sick of TB. International Journal Of Infectious Diseases 2015, 32: 147-151. PMID: 25809771, DOI: 10.1016/j.ijid.2014.12.003.Peer-Reviewed Original ResearchMeSH KeywordsExtensively Drug-Resistant TuberculosisFemaleHealth PersonnelHumansInfection ControlInfectious Disease Transmission, Patient-to-ProfessionalPrevalenceRiskTuberculosis, Multidrug-ResistantConceptsDrug-resistant tuberculosisInfection control measuresHealthcare workersLife-threatening diagnosisRisk of tuberculosisOccupational tuberculosisTB diseaseTreatment optionsTB epidemicPrevalent exposureHealthcare colleaguesHealthcare resourcesUrgent interventionTuberculosisControl measuresInterventionPervasive stigmatizationFront-line workersDiseaseDiagnosisWorkers
2013
Aspiring to Zero Tuberculosis Deaths among Southern Africa's Miners: Is There a Way Forward?
Dharmadhikari A, Smith J, Nardell E, Churchyard G, Keshavjee S. Aspiring to Zero Tuberculosis Deaths among Southern Africa's Miners: Is There a Way Forward? International Journal Of Social Determinants Of Health And Health Services 2013, 43: 651-664. PMID: 24397232, DOI: 10.2190/hs.43.4.d.Peer-Reviewed Original ResearchMeSH KeywordsAfrica, SouthernComorbidityDisease ProgressionEarly DiagnosisHIV InfectionsHousingHumansImmunocompromised HostLatent TuberculosisMaleMiningOccupational DiseasesOccupational Health ServicesSecondary PreventionSilicosisSocial ConditionsTuberculosisTuberculosis, Multidrug-ResistantWorkforceConceptsTuberculosis notification ratesNotification ratesDrug-resistant strainsSpread of tuberculosisHigh rateTuberculosis deathsActive tuberculosisHIV infectionSouth African minersImmediate treatmentTuberculosis diseaseConcurrent treatmentTuberculosis mortalityGeneral populationAppropriate managementTuberculosisSilica dustActive casesBiomedical interventionsDiseaseDeathAirborne diseasesInfectionPoor workingAfrican miners
2011
Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis.
Smith JP. Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis. The Yale Journal Of Biology And Medicine 2011, 84: 361-9. PMID: 22180674, PMCID: PMC3238330.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntitubercular AgentsDrug Delivery SystemsDrug Resistance, MicrobialHumansMycobacterium tuberculosisNanoparticlesTuberculosis, Multidrug-ResistantConceptsDrug-resistant tuberculosisCurrent chemotherapyAnti-TB drug candidatesAnti-tuberculosis chemotherapyDuration of treatmentDrug-resistant strainsGlobal health communityPill burdenPatient adherenceTuberculosis chemotherapyChemotherapyDrug resistanceIncomplete treatmentPotential mediatorsHealth communityNanoparticle drug deliveryTuberculosisDrug candidatesDevelopment pipelineNanoparticle deliveryTreatmentDeliveryDrug delivery